International News丨Colorectal cancer vaccine is expected to be approved within 2 years! Clinical trials are underway in these two countries!

Therapeutic colorectal cancer vaccine: If successful, it will be approved for marketing within 2 years.

Bowel cancer (colorectal cancer) is a cancer that causes 1.2 million cases each year, making it the third most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide. In terms of the site of onset, rectal cancer accounts for 49.66%, colon cancer accounts for 49.09%, and both account for 1.25%. The 5-year survival rate of this cancer that can be detected through early screening varies greatly - the 5-year survival rate of patients with localized colorectal cancer that can be surgically removed is about 90%, while the 5-year survival rate of patients with advanced colorectal cancer who have lost the opportunity for surgical treatment drops to 10%. Faced with this cancer with a high incidence and high risk of death, the National Health Service (NHS) of the United Kingdom announced that it will invite 44 bowel cancer patients to participate in an early breakthrough therapeutic vaccine study at 10 registration sites in the UK and Australia (6 in Australia and 4 in the UK) over the next 18 months. This vaccine, called "PD1-Vaxx" (also known as "MVF-PD-1(92-110)"), is not prepared from traditional pathogen antigens, but an anti-PD-1 B cell epitope. Its mechanism is to treat tumor patients who overexpress programmed cell death protein 1 (PD-L1) (in simple terms, it prevents tumor cells from escaping immune cell attacks, allowing immune cells to kill cancer cells normally).

Image source: PMC9137037

Previously, this vaccine was able to induce high-affinity polyclonal antibodies with similar efficacy to PD-1 monoclonal antibodies in mouse animal models, and its immunogenicity and anti-tumor properties were tested in the BALB/c syngeneic mouse model of CT26 colon cancer. This time, PD1-Vaxx will be used for eligible colorectal cancer patients to receive three doses of vaccination before surgery. I hope that in two years, this cancer vaccine will be successful and available on the market to benefit more cancer patients.

willing

=Pill=

Disclaimer: This article was created out of personal interest, only to help more ordinary people have a clearer understanding of vaccines. The content and views do not represent any organization, unit, or institution, and it has not accepted any form of sponsorship. All pictures are from public online platforms. If the content is incorrect, please do more self-criticism (not).